High expression of class III β-tubulin in small cell lung carcinoma

Oncology Letters

Volumn 7, Issue 2, 2014, Pages 405-410

  Powell, Steven ^a,b   Kaizer, Alex ^c   Koopmeiners, Joseph S ^c   Iwamoto, Carlos ^b   Klein, Mark ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b A VA HSR and D Center of Excellence   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Class III tubulin; Microtubule inhibitor; Small cell lung carcinoma

Indexed keywords

BETA TUBULIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN EXPRESSION; SCORING SYSTEM;

EID: 84890330544     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1734     Document Type: Article

References (32)

1. Argiris A and Murren JR: Staging and clinical prognostic factors for small-cell lung cancer. Cancer J 7: 437-447, 2001.
2. Chute JP, Chen T, Feigal E, Simon R and Johnson BE: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 17: 1794-1801, 1999.
3. Smyth JF: Chemotherapy of small cell lung cancer. Chest96(Suppl1): 61S-62S, 1989.
4. Katsetos CD, Legido A, Perentes E and Mörk SJ: Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. JChild Neurol 18: 851-866, 2003.
5. Burkhart CA, Kavallaris M and Horwitz SB: The role of beta-tubulin isotypes in resistance to antimitotic drugs. BiochimBiophys Acta 1471: 1-9, 2001.
6. Bernard-Marty C, Treilleux I, Dumontet C, et al: Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. ClinBreast Cancer 3: 341-345, 2002.
7. Ohishi Y, Oda Y, Basaki Y, et al: Expression of beta-tubulin isotypes in human primary ovarian carcinoma. GynecolOncol105: 586-592, 2007.
8. Koh Y, Kim TM, Jeon YK, et al: Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. AnnOncol20: 1414-1419, 2009.
9. Sève P, Reiman T, Lai R, et al: Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 60: 27-34, 2007.
10. Sève P and Dumontet C: Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? LancetOncol9: 168-175, 2008.
11. Sève P, Lai R, Ding K, et al: Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 13: 994-999, 2007.
12. Dumontet C, Isaac S, Souquet PJ, et al: Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92: E25-E30, 2005.
13. Rosell R, Scagliotti G, Danenberg KD, et al: Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22: 3548-3553, 2003.
14. Sève P, Isaac S, Trédan O, et al: Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. ClinCancer Res 11: 5481-5486, 2005.
15. Sève P, Mackey J, Isaac S, et al: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. MolCancerTher4: 2001-2007, 2005.
16. Katsetos CD, Kontogeorgos G, Geddes JF, et al: Differential distribution of the neuron-associated class III beta-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med 124: 535-544, 2000.
17. Zelen M: Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 4: 31-42, 1973.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
19. Urano N, Fujiwara Y, Doki Y, et al: Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. IntJOncol28: 375-381, 2006.
20. Leandro-García LJ, Leskelä S, Landa I, et al: Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken) 67: 214-23, 2010.
21. Raspaglio G, Filippetti F, Prislei S, et al: Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. Gene 409: 100-108, 2008.
22. Levallet G, Bergot E, Antoine M, et al: High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol Cancer Ther 11: 1203-1213, 2012.
23. Pentheroudakis G, Batistatou A, Kalogeras KT, et al: Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Res Treat 127: 179-193, 2011.
24. Ettinger DS, Finkelstein DM, Sarma RP and Johnson DH: PhaseII study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. JClinOncol13: 1430-1435, 1995.
25. Kirschling RJ, Grill JP, Marks RS, et al: Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol 22: 517-522, 1999.
26. Graziano SL, Herndon JE II, Socinski MA, et al: Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. JThoracOncol 3: 158-162, 2008.
27. Thomas P, Castelnau O, Paillotin D, et al: Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study. JClinOncol19: 1320-1325, 2001.
28. Stinchcombe TE, Mauer AM, Hodgson LD, et al: Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. JThoracOncol 3: 1301-1307, 2008.
29. Evans WK, Shepherd FA, Feld R, Osoba D, Dang P and DeboerG: VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 3: 1471-1477, 1985.
30. Smith IE, Evans BD, Gore ME, et al: Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol 5: 185-189, 1987.
31. Rivera E, Lee J and Davies A: Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 13: 1207-1223, 2008.
32. Dumontet C, Jordan MA and Lee FF: Ixabepilone: targeting beta III-tubulin expression in taxane-resistant malignancies. MolCancer Ther 8: 17-25, 2009.